null
Loading... Please wait...
FREE SHIPPING on All Unbranded Items LEARN MORE
Print This Page

The Biotech Investor (How to Profit from the Coming Boom in Biotechnology)

List Price: $23.00
SKU:
9780805075083
Quantity:
Minimum Purchase
25 unit(s)
  • Availability: Confirm prior to ordering
  • Branding: minimum 50 pieces (add’l costs below)
  • Check Freight Rates (branded products only)

Branding Options (v), Availability & Lead Times

  • 1-Color Imprint: $2.00 ea.
  • Promo-Page Insert: $2.50 ea. (full-color printed, single-sided page)
  • Belly-Band Wrap: $2.50 ea. (full-color printed)
  • Set-Up Charge: $45 per decoration
FULL DETAILS
  • Availability: Product availability changes daily, so please confirm your quantity is available prior to placing an order.
  • Branded Products: allow 10 business days from proof approval for production. Branding options may be limited or unavailable based on product design or cover artwork.
  • Unbranded Products: allow 3-5 business days for shipping. All Unbranded items receive FREE ground shipping in the US. Inquire for international shipping.
  • RETURNS/CANCELLATIONS: All orders, branded or unbranded, are NON-CANCELLABLE and NON-RETURNABLE once a purchase order has been received.
  • Product Details

    Author:
    Tom Abate
    Format:
    Paperback
    Pages:
    304
    Publisher:
    Henry Holt and Co. (January 1, 2004)
    Language:
    English
    ISBN-13:
    9780805075083
    ISBN-10:
    0805075089
    Weight:
    13.92oz
    Dimensions:
    5.5" x 8.5" x 0.69"
    Case Pack:
    26
    File:
    Macmillan Trade-Macmillan_Print_US_Trade_20260316161400-20260317.xml
    Folder:
    Macmillan Trade
    List Price:
    $23.00
    As low as:
    $17.71
    Publisher Identifier:
    P-STM
    Discount Code:
    A
    Audience:
    General/trade
    QuickShip:
    Yes
    Pub Discount:
    65
    Imprint:
    Holt Paperbacks
  • Overview

    "Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner." —Thom Calandra, editor in chief, CBS MarketWatch

    In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.
    Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He shares strategies for
    • tracking the effect of breaking news and the NASDAQ
    • anticipating drug trial announcements and FDA approvals
    • assessing the potential market, patent rights, and distribution deals for a drug
    He looks beyond medicine to biotech-related opportunities in everything from agriculture to jean manufacturing to software development. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.